Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126

Cancer Gene Therapy

Volumn 17, Issue 9, 2010, Pages 633-644

  Ito, M ^a   Zhao, N ^a   Zeng, Z ^a   Chang, C C ^a   Zu, Y ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Anaplastic large cell lymphoma (ALCL); anaplastic lymphoma kinase (ALK); ERK1 2 pathway; kinase inhibitor U0126; small interference RNA (siRNA) induced gene silencing; synergistic growth effect

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; BETA ACTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; SHORT HAIRPIN RNA; STAT3 PROTEIN; TRANSCRIPTION FACTOR JUNB;

ALK GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER MODEL; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG POTENTIATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; LOW DRUG DOSE; LYMPHOMA CELL; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BUTADIENES; CELL LINE, TUMOR; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; COMBINED MODALITY THERAPY; DRUG SYNERGISM; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE SILENCING; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MICE; MICE, INBRED BALB C; MICE, NUDE; NITRILES; PROTEIN-TYROSINE KINASES; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955920848     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.20     Document Type: Article

References (29)

1. Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K et al. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000; 96: 3681-3695.
2. Delsol G, Jaffe ES, Faini B, Gascoyne RD, Muller-Hermelink HK, Stein H et al. Anaplastic large cell lymphoma (ALCL), ALK positive. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). WHO Classification of Tumors of Haematopoietic and Lymphod Tissues. WHO Press: Lyon, 2008, pp 312-316.
3. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-1284.
4. Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997; 14: 2175-2188.
5. Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 2001; 20: 5623-5637. Review.
6. Fujimoto J, Shiota M, Iwahara T, Seki N, Satoh H, Mori S et al. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci USA 1996; 93: 4181-4186.
7. Kuefer MU, Look AT, Pulford K, Behm FG, Pattengale PK, Mason DY et al. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 1997; 90: 2901-2910.
8. Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 2003; 101: 1919-1927.
9. Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 2007; 110: 2259-2267. Review.
10. Shulman LN, Frisard B, Antin JH, Wheeler C, Pinkus G, Magauran N et al. Primary Ki-1 anaplastic large-cell lymphoma in adults: clinical characteristics and therapeutic outcome. J Clin Oncol 1993; 11: 937-942.
11. Reiter A, Schrappe M, Tiemann M, Parwaresch R, Zimmermann M, Yakisan E et al. Successfull treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 1994; 12: 899-908.
12. Hannon GJ. RNA interference. Nature 2002; 418: 244-251. Review.
13. Zamore PD. Ancient pathways programmed by small RNAs. Science 2002; 296: 1265-1269.
14. Ritter U, Damm-Welk C, Fuchs U, Bohle RM, Borkhardt A, Woessmann W. Design and evaluation of chemically synthesized siRNA targeting the NPM-ALK fusion site in anaplastic large cell lymphoma (ALCL). Oligonucleotides 2003; 13: 365-373.
15. Piva R, Chiarle R, Manazza AD, Taulli R, Simmons W, Ambrogio C et al. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood 2006; 107: 689-697.
16. Hsu FY, Zhao Y, Anderson WF, Johnston PB. Down-regulation of NPM-ALK by shRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro. Cancer Invest 2007; 25: 240-248.
17. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998; 273: 18623-18632.
18. Morgan R, Smith SD, Hecht BK, Christy V, Mellentin JD, Warnke R et al. Lack of involvement of the c-fms and N-myc genes by chromosomal translocation t(2;5)(p23;q35) common to malignancies with features of so-called malignant histiocytosis (SUDHL-1). Blood 1989; 73: 2155-2164.
19. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 2000; 96: 4319-4327.
20. Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002; 21: 1038-1047.
21. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005; 11: 623-629.
22. Watanabe M, Sasaki M, Itoh K, Higashihara M, Umezawa K, Kadin ME et al. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Cancer Res 2005; 65: 7628-7634.
23. Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001; 108: 851-859.
24. Horiuchi H, Kawamata H, Fujimori T, Kuroda Y. A MEK inhibitor (U0126) prolongs survival in nude mice bearing human gallbladder cancer cells with K-ras mutation: analysis in a novel orthotopic inoculation model. Int J Oncol 2003; 23: 957-963.
25. Dai Y, Chen S, Pei XY, Almenara JA, Kramer LB, Venditti CA et al. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood 2008; 112: 2439-2449.
26. Wentz SC, Wu H, Yip-Schneider MT, Hennig M, Klein PJ, Sebolt-Leopold J et al. Targeting MEK is effective chemo-prevention of hepatocellular carcinoma in TGF-alpha-transgenic mice. J Gastrointest Surg 2008; 12: 30-37.
27. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004; 22: 4456-4462.
28. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005; 23: 5281-5293.
29. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR et al. Phase I pharmacokinetic and pharmacody-namic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008; 26: 2139-2146.